Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
WuXi AppTec H | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$169.67B | 19.9x | -1.37 | HK$58.55 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 6.7% Upside | Upgrade to Pro+ | |
WuXi Biologics | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$87.26B | 22.9x | -0.84 | HK$21.80 | 2.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 1.6% Upside | Upgrade to Pro+ | |
Akeso | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$58.30B | -74.9x | 0.54 | HK$64.55 | -0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 14.8% Upside | Upgrade to Pro+ | |
Pharmaron Beijing Co Ltd | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$50.56B | 25.3x | 1.07 | HK$15.56 | 4.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 25.2% Upside | Upgrade to Pro+ | |
Tigermed | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$49.94B | 49.3x | -0.75 | HK$30.45 | 3.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 33.9% Upside | Upgrade to Pro+ | |
Sichuan Kelun Biotech | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$40.48B | -188x | -2.98 | HK$181.30 | 1.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 27.6% Upside | Upgrade to Pro+ | |
Genscript Biotech Corp | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$23.35B | -16.6x | -3.58 | HK$10.92 | 1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Joinn Laboratories China Co | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$14.53B | -18,500x | HK$9.97 | 4.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -8.2% Downside | Upgrade to Pro+ | ||
Beigene | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$14.46B | -0.3x | -1.77 | HK$136 | -1.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 27% Upside | Upgrade to Pro+ | |
Remegen | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$13.44B | -5.5x | 0.48 | HK$15.58 | 7.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Lepu Biopharma | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$12.78B | -49.2x | -0.76 | HK$2.98 | 1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Lepu Biopharma | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$12.78B | -49.2x | -0.76 | HK$2.98 | 1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Ascentage Pharma | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$12.57B | -25.5x | -0.53 | HK$36.70 | -1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 39.8% Upside | Upgrade to Pro+ | |
Innocare | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$12.01B | -28.9x | -0.83 | HK$5.91 | 3.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 44.6% Upside | Upgrade to Pro+ | |
Keymed Biosciences | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$8.71B | -13.4x | 0.06 | HK$32.40 | 2.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
TYK Medicines | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$8.21B | -11x | HK$22.55 | 1.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
CARsgen Therapeutics Holdings | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$5.13B | -8.1x | -0.28 | HK$9.66 | 3.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 9.5% Upside | Upgrade to Pro+ | |
Jiangsu Recbio Technology | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$3.88B | -6.8x | -0.46 | HK$8.26 | 2.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Alphamab | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$3.48B | -13.9x | -38.88 | HK$3.79 | 4.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -5.5% Downside | Upgrade to Pro+ | |
Frontage Holdings | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$3.36B | 40.4x | -1.09 | HK$1.65 | -0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -39.9% Downside | Upgrade to Pro+ | |
Biocytogen Pharmaceuticals Beijing | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$3.08B | -11.4x | -0.22 | HK$7.61 | -1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Abbisko Cayman | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$3.05B | -180x | -1.81 | HK$4.84 | -0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
CStone | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$3.01B | -18.2x | -0.24 | HK$2.52 | 6.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 6.8% Upside | Upgrade to Pro+ | |
ImmuneOnco Biopharmaceuticals | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$2.22B | -5.4x | -8.61 | HK$5.78 | 6.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Hua Medicine | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$1.51B | -5.3x | 0.14 | HK$1.58 | 4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Qyuns Therapeutics | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$1.49B | -11x | HK$6.70 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Wuhan YZY Biopharma | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$1.42B | -5.8x | -0.97 | HK$7.32 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Tot Biopharm Intl | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$1.31B | 142.2x | 1.16 | HK$1.87 | 10% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 38.3% Upside | Upgrade to Pro+ | |
Jacobio Pharmaceuticals Group | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$1.25B | -2.7x | -0.24 | HK$1.65 | 4.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 16.9% Upside | Upgrade to Pro+ | |
Mabpharm | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$1.24B | -5.9x | 0.84 | HK$0.30 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Immunotech | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$1.18B | -4.6x | 0.99 | HK$2.59 | 12.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Genor Biopharma Holdings | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$929.83M | -1.5x | -0.14 | HK$1.80 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Brii Biosciences | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$850.64M | -2.4x | -0.16 | HK$1.20 | 2.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -16.6% Downside | Upgrade to Pro+ | |
Sunho Biologics | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$638.83M | -3.5x | HK$4.19 | -1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
HighTide Therapeutics | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$617.72M | -0.7x | -0.11 | HK$1.21 | 0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Jw Cayman | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$615M | -0.9x | -0.04 | HK$1.60 | 5.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Antengene | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$523.17M | -0.8x | -0.04 | HK$0.81 | 5.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Kintor Pharma | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$394M | -0.6x | 0.01 | HK$0.93 | 2.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Clover Biopharmaceuticals | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$295.73M | -0.4x | 0.01 | HK$0.24 | 5.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Sirnaomics | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$273.38M | -0.4x | -0.15 | HK$2.65 | 1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
China Health Inc | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$193.10M | -3.2x | 0.01 | HK$0.19 | -1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |